Relapsed Multiple Myeloma Clinical Trial
Official title:
A Randomized, Controlled, Open-Label Phase 3 Study of Melflufen in Combination With Daratumumab Compared With Daratumumab in Patients With Relapsed or Relapsed-Refractory Multiple Myeloma
This was a randomized, controlled, open-label, Phase 3 multicenter study which enrolled patients with Relapsed-Refractory Multiple Myeloma (RRMM) who were either double refractory to an Immunomodulatory Drug (IMiD) and a Proteasome Inhibitor (PI) (regardless of the number of prior lines of therapy), or had received at least 3 prior lines of therapy including an IMiD and a PI. Patients received treatment with melflufen+dexamethasone+daratumumab or daratumumab until documented progressive disease, unacceptable toxicity, or patient/treating physician decision. Patients in the daratumumab treatment arm had the option to receive treatment with melflufen+dexamethasone+daratumumab after confirmed progressive disease.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04083534 -
First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06119685 -
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05577000 -
Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT01118689 -
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
|
Phase 1 | |
| Withdrawn |
NCT04802031 -
Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT02401295 -
ATRA, Celecoxib, and Itraconazole as Maintenance
|
Phase 1 | |
| Active, not recruiting |
NCT00603447 -
Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma
|
Phase 1 | |
| Active, not recruiting |
NCT02722668 -
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
|
Phase 2 | |
| Active, not recruiting |
NCT04965155 -
A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone)
|
Phase 2 | |
| Completed |
NCT00592579 -
A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma
|
Phase 2 | |
| Not yet recruiting |
NCT06433947 -
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT06304636 -
Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT03158688 -
Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.
|
Phase 3 | |
| Completed |
NCT04434469 -
A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT01080391 -
Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
|
Phase 3 | |
| Not yet recruiting |
NCT06348108 -
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT01949532 -
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease
|
Phase 1 | |
| Active, not recruiting |
NCT04398485 -
A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT03091933 -
Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)
|
Phase 1/Phase 2 | |
| Completed |
NCT01272466 -
Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma
|
Phase 1/Phase 2 |